Plain-English translation of NCT07460362 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combined with can help people with a difficult-to-treat form of lymphoma called mantle cell lymphoma. You would be eligible if your lymphoma has come back or stopped responding to previous treatments, including a type of drug called a BTK inhibitor. The study wants to see how well this medication combination works and what side effects it causes.
Mantle cell lymphoma is an aggressive cancer, and many patients' cancers stop responding to standard treatments or come back after initial therapy. Researchers are testing this new medication combination to give patients with hard-to-treat lymphoma another option that might work better.
You likely qualify if…
You likely don't qualify if…
You would take the two medications as an outpatient, likely visiting the clinic regularly for treatment cycles and monitoring blood tests. The study will check how well the medications are working and watch for side effects throughout your participation. Researchers will also test your blood for biomarkers that might help predict how you'll respond to the treatment.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China